165 related articles for article (PubMed ID: 12017210)
1. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
Achimastos A; Liberopoulos E; Nikas S; Bairaktari E; Miltiadous G; Tsimihodimos V; Elisaf M
Curr Med Res Opin; 2002; 18(2):59-63. PubMed ID: 12017210
[TBL] [Abstract][Full Text] [Related]
2. The effects of the addition of losartan on uric acid metabolism in patients receiving indapamide.
Nikas S; Rizos E; Milionis H; Bairaktari E; Kalaitzidis R; Siamopoulos K; Elisaf M
J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):289-91. PubMed ID: 11881040
[TBL] [Abstract][Full Text] [Related]
3. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia.
Elisaf M; Tsimichodimos V; Bairaktari E; Siamopoulos KC
J Cardiovasc Pharmacol; 1999 Jul; 34(1):60-3. PubMed ID: 10413068
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
[TBL] [Abstract][Full Text] [Related]
5. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
Paragh G; Seres I; Harangi M; Balogh Z; Illyés L; Boda J; Szilvássy Z; Kovács P
Diabetes Metab; 2003 Dec; 29(6):613-8. PubMed ID: 14707891
[TBL] [Abstract][Full Text] [Related]
6. [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].
Li LJ; Chen H; Ren JY; Wang L; Luo Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):541-4. PubMed ID: 19829670
[TBL] [Abstract][Full Text] [Related]
7. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Adkins JC; Faulds D
Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964
[TBL] [Abstract][Full Text] [Related]
8. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
[TBL] [Abstract][Full Text] [Related]
9. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Vega GL; Ma PT; Cater NB; Filipchuk N; Meguro S; Garcia-Garcia AB; Grundy SM
Am J Cardiol; 2003 Apr; 91(8):956-60. PubMed ID: 12686335
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
[TBL] [Abstract][Full Text] [Related]
11. Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases.
Ka T; Inokuchi T; Tsutsumi Z; Takahashi S; Moriwaki Y; Yamamoto T
Int J Clin Pharmacol Ther; 2006 Jan; 44(1):22-6. PubMed ID: 16425967
[TBL] [Abstract][Full Text] [Related]
12. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
[TBL] [Abstract][Full Text] [Related]
14. Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.
Kiortsis DN; Elisaf MS
Fundam Clin Pharmacol; 2001 Dec; 15(6):401-3. PubMed ID: 11860528
[TBL] [Abstract][Full Text] [Related]
15. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.
Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
Atherosclerosis; 2004 Feb; 172(2):273-9. PubMed ID: 15019537
[TBL] [Abstract][Full Text] [Related]
16. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
[TBL] [Abstract][Full Text] [Related]
17. Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
Tan CE; Chew LS; Tai ES; Chio LF; Lim HS; Loh LM; Shepherd J
Atherosclerosis; 2001 Feb; 154(2):469-74. PubMed ID: 11166781
[TBL] [Abstract][Full Text] [Related]
18. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Milionis HJ; Papakostas J; Kakafika A; Chasiotis G; Seferiadis K; Elisaf MS
J Clin Pharmacol; 2003 Aug; 43(8):825-30. PubMed ID: 12953339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
